Financial Shenanigans

Financial Shenanigans

ASMPT's FY2025 accounts are clean at the audit level but stretched at the presentation level. Deloitte issued an unqualified opinion with no emphasis of matter; the only "restatement" is the mechanical reclassification of NEXX as a discontinued operation; no short-seller report, regulatory action, or class-action filing exists. Yet underneath HKFRS continuing-operations EPS of HK$2.61 (more than triple the prior year) sits a single HK$1,113.5M gain on the AAMI joint-venture disposal supplying 92% of pre-tax profit, a working-capital outflow that turned operating cash flow into a HK$139M free cash burn, restructuring charges recurring for at least four consecutive years, and a near-doubling of trade receivables overdue more than 90 days. Nothing is hidden — management adjusts the gain out of its own non-HKFRS measures — but anchoring on HKFRS EPS will materially overstate run-rate earnings power.

1. The Forensic Verdict

Verdict: Watch (35/100). Accounting is fairly stated; reported profit and reported cash flow tell different stories about FY2025 underlying performance. Grade moves to Elevated if (a) FY2026 H1 working capital absorbs more than HK$500M, (b) past-due >90 day receivables continue to grow, or (c) the SMT divestiture produces a fresh "non-recurring" restructuring charge of similar magnitude. Grade returns to Clean if FY2026 CFO/NI exceeds 1.0x and restructuring drops below 1% of revenue.

No red flags, seven yellow, six green. The three valuation-relevant yellows cluster: a one-time JV gain pushing reported profit, a sharp working-capital drain, and recurring "non-recurring" charges. The cleanest tests are revenue recognition, related-party exposure, and operating-vs-financing cash-flow classification.

2. Breeding Ground

Governance is sound on paper but unusually crowded with transitions, lifting the risk that one-time items get steered into "non-recurring" buckets during a leadership reset.

Mitigants are credible: Big 4 auditor with no qualification, ASM International anchor with two NEDs, HKEX listing with SFC backstop. Compensation leans on revenue and operating margin, but the PSP relative-performance test caps headline-management benefit.

3. Earnings Quality

Reported HKFRS continuing earnings rose 273% YoY to HK$1,085M. Roughly 91% of that increase came from a single non-operating gain.

Stripping the JV gain, AEC inventory write-off, restructuring, and impairments produces "underlying" continuing PBT of HK$586M vs HK$559M — 4.8% growth, not the 167% headline. Management's non-HKFRS adjusted net profit (HK$467M FY25 vs HK$375M FY24) tracks this underlying picture.

Receivables grew 13% on 10% revenue growth — a 3pp gap, not itself diagnostic. The deeper signal is the aging table: trade receivables overdue >90 days jumped 69%, from HK$195M to HK$330M; total past-due balances reached HK$981M against gross trade receivables of HK$3,552M. Management classifies these debtors as "likely to make payment" using internally developed information; FY2026 collections will test that judgment.

Finished-goods inventory rose 47% (HK$890M to HK$1,312M) while raw materials slightly declined and work-in-progress was flat. In an equipment business that recognizes revenue on customer acceptance, a finished-goods spike is consistent with year-end shipments awaiting acceptance — supported by the H2 2025 bookings ramp and book-to-bill of 1.05 — but it is also the line where stale or obsolete inventory tends to accumulate before an inventory write-off. The HK$73.9M Q3 AEC write-off, triggered by the voluntary liquidation of ASMPT Equipment (Shenzhen), shows the channel is live.

4. Cash Flow Quality

The cash-flow statement is the most informative document in the FY2025 report: record reported profit, negative free cash flow.

CFO/NI fell from 2.98x in FY2024 to 0.27x in FY2025, and FCF/NI moved from 1.98x to negative. The mechanical driver is working capital.

The collapse from -HK$74M to -HK$988M is driven by three real items (receivables, inventory, restructuring cash-out) partially offset by two presentation items (payables stretch, customer advances). Strip the HK$456M customer-advance build (legitimate, tied to bookings) and the HK$533M payables stretch, and the underlying cash drag is closer to -HK$1.9B in working capital absorption. That is the lifeline test: if FY2026 bookings and advances normalize but receivables remain elevated, CFO will compress again.

The AAMI disposal contributed HK$862M of investing-line cash. Without it, FY2025 free cash flow (CFO minus PPE and intangible capex) was -HK$251M against HK$576M in FY2024. Reported dividends of HK$242M plus the HK$0.79 special dividend recommended at the AGM (~HK$330M assuming 417M shares) cannot be funded from underlying operations on the FY2025 trajectory — they are funded by disposal cash and existing balance-sheet liquidity.

Disclosure is clean: AAMI cash sits in investing, the gain is separately stated above operating profit. The risk is a reader missing that the cash position grew via asset sale, not business cash generation.

Notes receivable discounted to banks with recourse fell from HK$181M to HK$19M, and the company correctly keeps the full carrying amount on the balance sheet with the bank cash treated as collateralized borrowing — this is the most conservative IFRS treatment for Chinese commercial-paper-style receivables discounting and is an evidence point against any "receivables-sales-disguised-as-CFO" concern. The HK$302M derecognition of borrowings in financing activities maps cleanly to the unwind of the discounted-notes balance.

5. Metric Hygiene

Management's non-HKFRS framework is unusually candid for an HK-listed name: line-itemized in the MD&A and — uniquely for FY2025 — producing an adjusted number lower than the HKFRS print because management excludes its own one-time gain.

The HKFRS-to-adjusted gap inverted between FY2024 and FY2025. FY2024 adjusted ran higher (restructuring and Rule 3.7 takeovers expenses added back); FY2025 adjusted runs lower (AAMI gain removed). Both are internally consistent — "adjusted" is the better run-rate proxy in both directions, and the FY2025 down-move is arithmetic, not marketing.

The new associate position (Shenzhen Original Advanced Compounds, 603991.SH, 18.99% stake, HK$2,076M carrying, HK$2,365M quoted fair value) is 7.9% of total assets. Equity-method accounting passes through only ASMPT's share of results; mark-to-market changes do not hit P&L. The carrying-to-fair-value gap is a soft barometer of unrealized gain/loss that lives entirely outside the income statement.

6. What to Underwrite Next

Monitoring items in priority order, and the calls each would change.

Accounting risk at ASMPT is a valuation-and-position-sizing item, not a thesis breaker. Underwriters should: (1) anchor forward multiples on adjusted net profit (HK$467M FY25 continuing), not HKFRS; (2) treat the HK$862M AAMI proceeds as one-time, not extrapolate net-cash growth; (3) require a clean FY2026 H1 working-capital print before sizing past a tactical position; (4) discount any "non-HKFRS adjusted" restructuring add-backs that recur for a fifth consecutive year. With those adjustments, the underlying business — semi-back-end equipment with leading TCB share and 21.7% bookings growth — is what is actually being bought. The forensic risk is the gap between headline and underlying number, not the integrity of the numbers.